The identification of genetic vulnerabilities in head and neck cancers for the development of novel therapies.
Lead Research Organisation:
Wellcome Sanger Institute
Department Name: Wellcome Trust Genome Campus
Abstract
Every year ~370,000 of the world population will die of head and neck squamous cell carcinoma (HNSCC), and of these more than 80% will be from the Asian sub-continent. In Malaysia, HNSCC is the second commonest form of cancer. Less than 50% of HNSCC patients will survive beyond 5 years after diagnosis, largely due to a lack of effective therapies for this cancer. There is compelling evidence that identifying the genes that are responsible for the survival and growth of cancer cells can help us develop new drugs, and more importantly determine which existing drugs are most effective for specific patients. Here, using cancer cells that were derived from Asian HNSCC patients, we will use newly developed powerful gene editing techniques to identify critical genes that are responsible for cancer survival, and where inhibiting these would result in cancer cell death or growth arrest. The identification of genes that are essential for cancer cell survival will result in identification of relevant existing drugs that could be re-purposed for the treatment of HNSCC. This approach would shorten the drug development markedly as the safety and efficacy profiles of these would already be well-documented. In addition, the knowledge of the genes that drive HNSCC would afford an opportunity to develop novel drugs that could be effective in the treatment of HNSCC.
Technical Summary
The global cancer burden is expected to double by the year 2030 and this will disproportionately affect the Asian continent. Head and neck squamous cell carcinoma (HNSCC) is endemic in Asia, and it is one of the top 3 cancers in Malaysia. Long-term survival of less than 50% and limited approved therapies for HNSCC underscore the urgent need for the development of novel and effective therapies. While the mutational landscape of HNSCC is now well established, the ability to identify the targetable component of the cancer genome will accelerate translation of these knowledge into clinical benefit. A major focus in the development of new cancer therapies has been the identification of essential genes that are critical for the survival of cancer cells, and where loss or inactivation of these can result in cell death or growth arrest.
This project will use state-of-the art biological models, genome-wide CRISPR/Cas9 lethality screens and next-generation sequencing, to address this major health problem in Asia. We will use experimental and computational approaches to identify essential genes for HNSCC and specific pharmacologic inhibitors that could target these genes. The successful completion of this project will form the basis of developing novel targeted drugs for HNSCC as well as re-purposing existing therapies currently used to treat other cancer types.
This project will use state-of-the art biological models, genome-wide CRISPR/Cas9 lethality screens and next-generation sequencing, to address this major health problem in Asia. We will use experimental and computational approaches to identify essential genes for HNSCC and specific pharmacologic inhibitors that could target these genes. The successful completion of this project will form the basis of developing novel targeted drugs for HNSCC as well as re-purposing existing therapies currently used to treat other cancer types.
Planned Impact
The identification of molecular therapies requires a good understanding of cancer biology and access to technology that enables the systematic evaluation of the role of each gene as a potential driver of cancer development. This partnership between Wellcome Trust Sanger Institute (WTSI) and Cancer Research Malaysia (CRM) will bring together cancer researchers who have a deep understanding of HNSCC and considerable experience working with this disease and individuals who have utilized powerful gene editing technologies to dissect the contribution of each gene to the cancer development process.
This partnership will immediately benefit the CRM head and neck cancer groups and their network of collaborators by enabling new technological advancements to be applied in identifying critical genes in cancers that are important in Malaysia and the wider region. This study will result in the training of two post-doctoral research scientists and a MSc student. The training of a researcher from CRM (Dr Vivian Tiong) has already been initiated through a Union for International Control/International Cancer Research Technology Transfer (UICC/ICRETT) fellowship in 2015 where Dr Tiong spent 10 weeks in Dr McDermott's laboratory in WTSI. It is anticipated that this proposal will generate local expertise in Malaysia in the use of genome-wide CRISPR lethality screens that at a future date could be extended to other cancer types in addition to HNSCC.
The results generated from this study will additionally benefit scientists and clinicians working on head and neck cancers and other cancers in general as the data will serve as a valuable resource to inform researchers about the possible genes that are responsible for maintaining cancer cell survival. While this study focuses on head and neck cancers, emerging evidence suggests that molecular pathways that are critical in one type of cancer could also be important in other cancer types.
Furthermore, such large data-sets would also be beneficial to pharmaceutical companies designing and developing therapeutic interventions. As the CRISPR/Cas9 technology is relatively new, the data generated here would add to existing information on essential genes in cancer, particularly those that can be targeted for cancer control. In the longer term all the available data taken together could accelerate the development of effective treatment strategies for HNSCC. This could be an avenue that provide economic competitiveness to the United Kingdom as drugs for the treatment of HNSCC is still very limited.
While it is not possible to include clinical validation within the limited duration of this 2-year study, we would hope that the results of this study will result in the identification of potential targets in HNSCC, both those where there are existing drugs and those that are truly novel . For the former, the long-term goal would be to re-purpose existing drugs for use in HNSCC within 3 years. This would be a significant advancement in the clinical field of HNSCC as there is currently only one targeted therapy approved for therapeutic use. For truly novel targets that are validated, an additional period of research that involves collaboration with medicinal chemistry (for chemical probe design) and in vivo model groups would be desirable. This would of necessity have to be the focus of a new research proposal.
This partnership will immediately benefit the CRM head and neck cancer groups and their network of collaborators by enabling new technological advancements to be applied in identifying critical genes in cancers that are important in Malaysia and the wider region. This study will result in the training of two post-doctoral research scientists and a MSc student. The training of a researcher from CRM (Dr Vivian Tiong) has already been initiated through a Union for International Control/International Cancer Research Technology Transfer (UICC/ICRETT) fellowship in 2015 where Dr Tiong spent 10 weeks in Dr McDermott's laboratory in WTSI. It is anticipated that this proposal will generate local expertise in Malaysia in the use of genome-wide CRISPR lethality screens that at a future date could be extended to other cancer types in addition to HNSCC.
The results generated from this study will additionally benefit scientists and clinicians working on head and neck cancers and other cancers in general as the data will serve as a valuable resource to inform researchers about the possible genes that are responsible for maintaining cancer cell survival. While this study focuses on head and neck cancers, emerging evidence suggests that molecular pathways that are critical in one type of cancer could also be important in other cancer types.
Furthermore, such large data-sets would also be beneficial to pharmaceutical companies designing and developing therapeutic interventions. As the CRISPR/Cas9 technology is relatively new, the data generated here would add to existing information on essential genes in cancer, particularly those that can be targeted for cancer control. In the longer term all the available data taken together could accelerate the development of effective treatment strategies for HNSCC. This could be an avenue that provide economic competitiveness to the United Kingdom as drugs for the treatment of HNSCC is still very limited.
While it is not possible to include clinical validation within the limited duration of this 2-year study, we would hope that the results of this study will result in the identification of potential targets in HNSCC, both those where there are existing drugs and those that are truly novel . For the former, the long-term goal would be to re-purpose existing drugs for use in HNSCC within 3 years. This would be a significant advancement in the clinical field of HNSCC as there is currently only one targeted therapy approved for therapeutic use. For truly novel targets that are validated, an additional period of research that involves collaboration with medicinal chemistry (for chemical probe design) and in vivo model groups would be desirable. This would of necessity have to be the focus of a new research proposal.
Publications
Description | New therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed. We conducted genome-wide CRISPR-Cas9 screens in 21 OSCC cell lines, primarily derived from Asians, to identify genetic vulnerabilities that can be explored as therapeutic targets. We identify known and novel fitness genes and demonstrate that many previously identified OSCC-related cancer genes are non essential and could have limited therapeutic value, while other fitness genes warrant further investigation for their potential as therapeutic targets. We validate a distinctive dependency on YAP1 and WWTR1 of the Hippo pathway, where the lost of-fitness effect of one paralog can be compensated only in a subset of lines. We also discover that OSCCs with WWTR1 dependency signature are significantly associated with biomarkers of favourable response towards immunotherapy. In summary, we have delineated the genetic vulnerabilities of OSCC, enabling the prioritization of therapeutic targets for further exploration, including the targeting of YAP1 and WWTR1. |
Exploitation Route | - identified new drug targets for head and neck cancers, in particularly OSCC - generated a new highly annotated collection of cell models from Asian patients for the study of head and neck cancer - new insights into functional redundancy within the Hippo signalling pathway can inform on therapeutic approaches targeting this pathway. - Identification of a subset of head and neck cancers which might be responsive to immunotherapy agents |
Sectors | Education,Pharmaceuticals and Medical Biotechnology |
Description | Determining the genetic vulnerabilities of head and neck cancer for therapeutic purposes |
Amount | RM250,000 (MYR) |
Organisation | Ong Hin Tiang and Ong Sek Pek Foundation |
Sector | Charity/Non Profit |
Country | Malaysia |
Start | 02/2018 |
End | 01/2021 |
Description | Joint Canadian-Israel Research Program |
Amount | $500,000 (CAD) |
Organisation | International Development Research Centre |
Sector | Public |
Country | Canada |
Start | 11/2022 |
End | 11/2026 |
Description | Mechanism-guided drug repurposing to accelerate the development of novel therapies for oral squamous cell carcinoma (OSCC) |
Amount | £75,676 (GBP) |
Funding ID | MR/V005936/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2020 |
End | 12/2021 |
Description | Ranjeet Bhagwan Singh Research Award |
Amount | RM49,490 (MYR) |
Organisation | Academy of Sciences Malaysia |
Sector | Public |
Country | Malaysia |
Start | 10/2021 |
End | 09/2023 |
Title | Cell Model Passport |
Description | Provided critical information on fusion genes present in cancer cell line models |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | - this database is widely used by hundreds of reearchers every month |
URL | https://cellmodelpassports.sanger.ac.uk/ |
Title | Oral cancer fitness genes |
Description | We have generated substantial data on the core fitness genes and selective fitness genes for oral cancer that can be used as a resource to study oral cancer. |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | No |
Impact | This would be a unique dataset derived mainly from Asian oral cancer cell lines where the disease is most prevalent. |
Description | CRISPR/Cas9 screens on nasopharyngeal cancer |
Organisation | University of Hong Kong |
Country | Hong Kong |
Sector | Academic/University |
PI Contribution | We have conducted CRISPR-Cas9 screens on nasopharyngeal carcinoma cell lines and these will be the only cancer dependency maps for this cancer thus far. |
Collaborator Contribution | The nasopharyngeal carcinoma cell lines were established by Prof George Tsao. |
Impact | The collaboration has resulted in cancer dependency maps for this cancer. |
Start Year | 2018 |
Description | The Cancer Dependency Map |
Organisation | Broad Institute |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | The results from this study have contribute to the Cancer Dependency Map which is an international collaboration with the Broad Institute (USA) to map all dependencies in cancer cells. |
Collaborator Contribution | The CRISPR datasets generated and genomic datasets have contributed to the dependency map. |
Impact | Reference datasets for the community that are widely used. |
Start Year | 2017 |
Description | Interview by national press |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | We received inquiries from the public about the status of our work. In addition, Malaysian scientists from abroad reached out to us on opportunities to return to Malaysia. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.thestar.com.my/news/2020/11/17/on-the-trail-of-an-oral-cancer-treatment |
Description | Interview on national radio |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Dr Ultan McDermott and myself were invited for an interview with Business FM (BFM) Malaysia to explain what the CRISPR/Cas9 gene editing technology and how our project to use CRISPR/Cas9 screens to identify genetic vulnerabilities in cancer cells could impact our understand of cancer development and treatment. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.bfm.my/ultan-mcdermott-cheong-sok-ching-head-neck-cancer.html |
Description | Interview on radio |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | We receive inquiries and invitation for further talks by societies and universities.We also received queries from local scientists for collaborative work. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.bfm.my/podcast/the-bigger-picture/health-and-living/targeting-genetic-vulnerabilities-in... |
Description | Invited speaker by the Malaysian Society for Biochemistry and Molecular Biology, Kuala Lumpur |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | During this talk about our findings from the CRISPR/Cas9 screens and how this is important for a cancer where there is currently limited therapeutic options. I also talked about the importance of working on a cancer that is more prevalent in our region and how that can ensure that these cancers do not get left behind in the fight against cancer. I highlighted the need for developing young talents to sustain the research environment in our region. |
Year(s) Of Engagement Activity | 2019 |
Description | Invited talk at UCSI University, Kuala Lumpur |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Undergraduate students |
Results and Impact | This talk was to expose undergraduate students and medical trainees to the CRISPR/Cas9 gene-editing technology and the impact it may have on medicine. This sparked some discussions on the ethical implications of using gene-editing, The students were impressed that Malaysian researchers conduct genome-wide CRISRP/Cas9 screens here in Malaysia. |
Year(s) Of Engagement Activity | 2019 |
Description | Invited talk by University of Peradeniya, Sri Lanka |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | I introduced the technology of gene-editing during this talk and discussed the need for therapeutic developmenf for an Asian cancer. |
Year(s) Of Engagement Activity | 2019 |
Description | Invited talk by the Asian Society of Oral & Maxillofacial Pathology, Kuala Lumpur |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on emerging novel therapeutic options for oral cancer was held during this meeting. As a result, Prof Cheong was invited to apply for the Presidents Award from the International Association of Oral Pathologists (IAOP). The results of this application is not known yet. |
Year(s) Of Engagement Activity | 2019 |
Description | Milner Therapeutics Symposium. Cambridge, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Private public initiative |
Year(s) Of Engagement Activity | 2018 |
Description | Online news |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | This is an online article describing our findings on identifying critical genes in oral cancer and explaining the science to the public, |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.freemalaysiatoday.com/category/nation/2020/11/16/malaysian-scientists-identify-genes-res... |
Description | Royal Society Conference: 'The CRISPR Revolution: Changing Life', London UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of scientists and policy makers at the Royal Society |
Year(s) Of Engagement Activity | 2018 |
Description | Royal Society conference: 'The CRISPR Revolution: Changing Life', London UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Public presentation and debate on the application of CRISPR technology adressing scientific, financial and ethical issues. |
Year(s) Of Engagement Activity | 2018 |
Description | Target Validation using Genomics and Informatics, Wellcome Genome Campus |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of the use of CRISPR screens to identify new drug targets |
Year(s) Of Engagement Activity | 2017 |
Description | Virtual Lab Tour at Cancer Research Malaysia |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | At this event, a lecture on cancer research in the area of precision medicine was given, followed by a virtual lab tour of our laboratory. |
Year(s) Of Engagement Activity | 2021 |
Description | Workshop on Scientific critical thinking and fundamentals of impactful biomedical research projects |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | I was invited to this event to share our experience in putting together impactful research projects which sparked interest amongst researchers in Malaysia. This resulted in several young scientists requesting one-on-one mentoring sessions which I conducted. |
Year(s) Of Engagement Activity | 2021 |